Formulation and evaluation of baclofen liposome vesicles using lecithin
DOI:
https://doi.org/10.30827/ars.v61i3.15279Palabras clave:
Lecithin, Cholesterol, Baclofen, Ethanol, Muscle Relaxant Activity.Resumen
Introduction: The main aim of present study was to prepare and characterize liposomal formulation of baclofen to improve the effectiveness of the topically applied formulation.
Method: For the preparation of liposomes, different ratio of lecithin, cholesterol and ethanol were taken but ratio of drug and stearic acid were kept constant and prepared by ethanol injection method. Liposomes were characterized for vesicle size, vesicle shape, entrapment efficiency, in vitro studies, stability studies and in vivo studies.
Results: The average particle size of formulated liposome was in the range of 3.98±0.45-4.24±0.65 µm and small unilamellar vesicles with spherical in shape observed. Entrapment efficiency of optimized formulation was 58.67±0.81 %. The maximum % cumulative drug release behaviours were 67.66±5.32 % after 10 h. formulation stored in 4±2 °C temperature shows better stability (64.19±0.26) compared to elevated temperature. Swiss albino mice were used for the in vivo study and exhibit muscle relaxant activity in terms of no. of falls from rota rod apparatus (p value =0.001).
Conclusions: Baclofen loaded liposomal formulation have shown skeletal muscle relaxant activity in mice suggesting delivery of baclofen from liposomes in the therapeutic range.
Descargas
Citas
Bangham AD, Horne RW. Negative staining of phospholipids and their structured modofication by surface active agents as observed in the electron microscope, J Mol Biol. 1964; 8: 660–8. doi: 10.1016/s0022-2836(64)80115-7
Schreier H, Bouwstra J. Liposomes and niosomes as drug carriers: dermal and transdermal drug delivery. J Control Rel. 1994; 30: 1–5. doi: 10.1016/0168-3659(94)90039-6
Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes improvement in pharmacokinetics and anti-tumor therapeutic efficacy. Proc Nutl Acad Sci. USA88, 1991; 11460-64. doi: 10.1073/pnas.88.24.11460
Freise CE, Hong K, Clemens LE, Papahadjopoulos D, Burke E,Martinez 0,Lake J,Ascher NL, Roberts JP. Characterization of a cyclosporine containing liposome. Transpla Proc.1991;23: 473-4.
Vadiei K, Lopez-Berestein G, Peres-Soler R, Luke DR. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Dru Metab Dispos. 1991; 19: 1147-51.
Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001; 90: 667–80. doi: 10.1002/jps.1023.
Robinson JR, Lee HL. Controlled Drug Delivery Fundamentals and Applications. Marcel Decker, New York. 1987; 2: 524-52. doi: 10.1002/jps.2600770119.
Jain NK. Controlled and Novel drug delivery. CBS Publisher and distributor, 1997; 1: 100-26.
Gannu R, Vamshi YV, Kishan V, Rao YM. Development of Nitrendipine transdermal Patches: In vitro and Ex vivo Characterization. Curr Drug Del. 2007; 4: 69-76. doi: 10.2174/156720107779314767.
BruntonLL, Lazo JS, Parker KL. The pharmacological basis of therapeutics, Agent acting at the neuromuscular junction and autonomic gaglia. Mc Graw hill, New York, 2006; 11: 217. doi: 10.1136/oem.2007.033902
Kumar A, Badde S, Kamble R, Pokharkar VB. Development and characterization of liposomal drug delivery system fornimesulide. Int J Pharm Pharm Sci. 2010; 2(4): 87-9.
Varsheny HM, Tanwar YS, lowalekar R, Rathore KS. Designing and characterization of verapamil hydrochloride niosomes. Ind. Pharm. 2007; 6: 77-9.
Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm. 2005; 290(1-2): 155-9. doi: 10.1016/j.ijpharm.2004.10.026.
Karki R, Mamatha GC, Subramanya G, Udupa N. Preparation, characterization and tissue diposition of niosomes containing isoniazide. Riverd Jew Cent. 2008; 1(2): 224-7.
Doijad RC, Manvi FV, Swathi S, Rony M. Niosomal drug delivery of cisplatin: development and characterization. Ind Drugs. 2008; 45(9): 713-8.
Vogel HG. Drug Discovery and Evaluation, Pharmacological Assays. 2nd. Ed. Springer-Verlag Berlin Heidelberg, New York, 2002; 398.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Los artículos que se publican en esta revista están sujetos a los siguientes términos en relación a los derechos patrimoniales o de explotación:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, la cual se distribuirá con una licencia Creative Commons BY-NC-SA 4.0 que permite a terceros reutilizar la obra siempre que se indique su autor, se cite la fuente original y no se haga un uso comercial de la misma.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la fuente original de su publicación.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en repositorios institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
